According to our latest research report “ Russian Pharma Sector Forecast to 2013”, the prevalence of Hepatitis C has been steadily increasing in Russia that causes a large number of deaths annually. The key reasons responsible for this are augmented usage of intravenous drugs, unhygienic lifestyle, and high–risk sexual activities. Half of the patients diagnosed with Hepatitis are aged between 11-30 years.
Our study indicates that, the Hepatitis C drug market is anticipated to mainly grow due to the sales of two drugs: Roche's Pegasys and Schering-Plough's PegIntron. It is estimated that, the market would grow at a CAGR of around 9% during 2009-2013, owing to an increase in the government spending on healthcare and high usage of more-expensive therapies, like pegylated interferons rather than conventional interferons.
Besides, we have done thorough research and prudent analysis of the Russian Pharma market and identified some critical factors acting as a catalyst for the industry’s current and future growth outlook. The report reveals that, the growth of the industry will be mainly driven by dynamic government support and increasing private investments. Further, various factors, such as growing healthcare spending and growth in the obligatory and voluntary insurance schemes have been resulting into the increasing usage of high-priced drugs in the country as well. Moreover, infectious diseases, like HIV/AIDS are on the rise and Russia is transforming a more conducive environment for clinical trials, which will further pave way for the growth of the pharmaceutical industry in the country. Our research unfolds various other drivers that would safeguard and promote the further growth of the industry.
Our report “Russian Pharma Sector Forecast to 2013” provides precise and reliable information, supplemented with statistics, regarding the Russian pharma sector. The report covers leading drugs, segment-wise break up, and information about major therapy areas. It has thoroughly examined current market trends; industrial developments, and competitive landscape to enable clients understand the market structure and its progress in coming years. Forecasts have been done considering the possible impact of recession on the industry. The report also presents a brief overview of demographics and healthcare profile to adjudge the pharmaceutical market in terms of demands, expenditure, and possible future direction.
For more information visit: http://www.rncos.com/Report/IM243.htm |
